Eucerin

DRUG2 trials

Sponsors

Memorial Sloan Kettering Cancer Center, Innovaderm Research Inc.

Conditions

Invasive Breast CancerPigmentation From Visible Light

Phase 3

Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation

CompletedNCT01856543

Memorial Sloan Kettering Cancer CenterInvasive Breast Cancer

Start: 2013-05-31End: 2017-01-31Updated: 2019-10-03

Unknown Phase

Vitamin E Prevention of Visible Light Pigmentation

CompletedNCT01927679

Innovaderm Research Inc.Pigmentation From Visible Light

Start: 2013-08-31End: 2013-11-30Updated: 2014-03-04